JP2017529365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529365A5 JP2017529365A5 JP2017515823A JP2017515823A JP2017529365A5 JP 2017529365 A5 JP2017529365 A5 JP 2017529365A5 JP 2017515823 A JP2017515823 A JP 2017515823A JP 2017515823 A JP2017515823 A JP 2017515823A JP 2017529365 A5 JP2017529365 A5 JP 2017529365A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- halo
- independently
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 387
- 125000001475 halogen functional group Chemical group 0.000 claims 123
- 125000001424 substituent group Chemical group 0.000 claims 59
- 229910052757 nitrogen Inorganic materials 0.000 claims 29
- 125000005842 heteroatom Chemical group 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 21
- 229910052760 oxygen Inorganic materials 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 11
- -1 R 21 Chemical compound 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims 1
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290279.0 | 2014-09-17 | ||
| EP14290279 | 2014-09-17 | ||
| PCT/EP2015/071349 WO2016042089A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic lrrk2 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529365A JP2017529365A (ja) | 2017-10-05 |
| JP2017529365A5 true JP2017529365A5 (enExample) | 2018-09-13 |
Family
ID=51752058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515823A Pending JP2017529365A (ja) | 2014-09-17 | 2015-09-17 | 大環状ｌｒｒｋ２キナーゼ阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10377772B2 (enExample) |
| EP (1) | EP3194405B1 (enExample) |
| JP (1) | JP2017529365A (enExample) |
| KR (1) | KR20170048599A (enExample) |
| CN (1) | CN107108641A (enExample) |
| AU (1) | AU2015316801B2 (enExample) |
| BR (1) | BR112017005299A2 (enExample) |
| CA (1) | CA2960777A1 (enExample) |
| DK (1) | DK3194405T3 (enExample) |
| EA (1) | EA032838B1 (enExample) |
| ES (1) | ES2717510T3 (enExample) |
| HU (1) | HUE043972T2 (enExample) |
| IL (1) | IL251054B (enExample) |
| MX (1) | MX2017003470A (enExample) |
| PL (1) | PL3194405T4 (enExample) |
| SG (1) | SG11201701936WA (enExample) |
| TR (1) | TR201904514T4 (enExample) |
| TW (1) | TW201625639A (enExample) |
| WO (1) | WO2016042089A1 (enExample) |
| ZA (1) | ZA201701841B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111221514B (zh) * | 2020-01-13 | 2023-03-03 | 陕西心像信息科技有限公司 | 基于OsgEarth的三维可视化组件实现方法及系统 |
| US20230126352A1 (en) * | 2020-01-31 | 2023-04-27 | Oncodesign Sa | Macrocyclic rip2-kinase inhibitors |
| BR112022022511A2 (pt) | 2020-05-06 | 2022-12-13 | Servier Lab | Inibidores macrocíclicos de lrrk2 quinase |
| BR112023017834A2 (pt) | 2021-03-18 | 2023-10-03 | Servier Lab | Inibidores de lrrk2 cinase macrocíclicos |
| EP4416133A1 (en) * | 2021-10-11 | 2024-08-21 | Baylor College of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
| JP2024541934A (ja) * | 2021-10-27 | 2024-11-13 | ハー・ルンドベック・アクチエゼルスカベット | Ｌｒｒｋ２阻害剤 |
| WO2023222005A1 (zh) * | 2022-05-18 | 2023-11-23 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
| TW202412777A (zh) * | 2022-09-15 | 2024-04-01 | 丹麥商Ｈ 朗德貝克公司 | 富白胺酸重複激酶2（lrrk2）抑制劑 |
| TW202442235A (zh) * | 2023-04-20 | 2024-11-01 | 丹麥商Ｈ 朗德貝克公司 | 富白胺酸重複激酶2（lrrk2）抑制劑 |
| WO2024218285A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (lrrk2) inhibitors |
| WO2024218290A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (lrrk2) inhibitors |
| WO2024218296A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| PT721331E (pt) | 1993-10-01 | 2002-05-31 | Astrazeneca Ab | Processo i |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| HU229024B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| ATE375345T1 (de) | 2000-12-28 | 2007-10-15 | Ono Pharmaceutical Co | Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-verbindun als crf-rezeptor antagonist |
| EP1395257A1 (en) * | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| US8029986B2 (en) | 2004-10-21 | 2011-10-04 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt(GmbH) | KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| FI123725B (fi) | 2005-08-01 | 2013-10-15 | Reijo Viljanen | Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet |
| WO2007058627A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Oxygen linked pyrimidine derivatives |
| WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| JP5752691B2 (ja) | 2009-09-29 | 2015-07-22 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 新規化合物 |
| ME03376B (me) * | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| HUE029728T2 (en) * | 2011-09-30 | 2017-03-28 | Ipsen Pharma Sas | Macrocyclic LRRK2 kinase inhibitors |
| BR112014007622A2 (pt) * | 2011-09-30 | 2017-04-04 | Oncodesign Sa | inibidores de flt3 cinase macrocíclicos |
-
2015
- 2015-09-17 ES ES15766801T patent/ES2717510T3/es active Active
- 2015-09-17 CN CN201580061216.1A patent/CN107108641A/zh active Pending
- 2015-09-17 US US15/511,879 patent/US10377772B2/en not_active Expired - Fee Related
- 2015-09-17 TW TW104130753A patent/TW201625639A/zh unknown
- 2015-09-17 AU AU2015316801A patent/AU2015316801B2/en not_active Ceased
- 2015-09-17 DK DK15766801.3T patent/DK3194405T3/en active
- 2015-09-17 PL PL15766801T patent/PL3194405T4/pl unknown
- 2015-09-17 HU HUE15766801A patent/HUE043972T2/hu unknown
- 2015-09-17 BR BR112017005299A patent/BR112017005299A2/pt not_active IP Right Cessation
- 2015-09-17 KR KR1020177010322A patent/KR20170048599A/ko not_active Withdrawn
- 2015-09-17 EP EP15766801.3A patent/EP3194405B1/en not_active Not-in-force
- 2015-09-17 CA CA2960777A patent/CA2960777A1/en not_active Abandoned
- 2015-09-17 SG SG11201701936WA patent/SG11201701936WA/en unknown
- 2015-09-17 EA EA201790626A patent/EA032838B1/ru not_active IP Right Cessation
- 2015-09-17 MX MX2017003470A patent/MX2017003470A/es unknown
- 2015-09-17 TR TR2019/04514T patent/TR201904514T4/tr unknown
- 2015-09-17 WO PCT/EP2015/071349 patent/WO2016042089A1/en not_active Ceased
- 2015-09-17 JP JP2017515823A patent/JP2017529365A/ja active Pending
-
2017
- 2017-03-09 IL IL251054A patent/IL251054B/en not_active IP Right Cessation
- 2017-03-15 ZA ZA2017/01841A patent/ZA201701841B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529365A5 (enExample) | ||
| JP2019536785A5 (enExample) | ||
| JP2016506369A5 (enExample) | ||
| JP2015509535A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| JP2012511588A5 (enExample) | ||
| JP2019501125A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| JP2016525135A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| JP2018519343A5 (enExample) | ||
| JP2018522034A5 (enExample) | ||
| JP2016510796A5 (enExample) | ||
| JP2014506599A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| JP2016507581A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2015504091A5 (enExample) | ||
| CR20200418A (es) | Inhibidores de orginasa y sus mètodos de uso antecedentes | |
| JP2017501237A5 (enExample) | ||
| JP2016531868A5 (enExample) | ||
| SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
| JP2019532067A5 (enExample) | ||
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a |